1478 related articles for article (PubMed ID: 22410028)
1. Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.
Kim JM; Kwon CH; Joh JW; Choi MS; Lee JH; Koh KC; Paik SW; Kim GS; Kim SJ; Lee SK; Yoo BC
Transplant Proc; 2012 Mar; 44(2):403-8. PubMed ID: 22410028
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma.
Dhanasekaran R; Khanna V; Kooby DA; Spivey JR; Parekh S; Knechtle SJ; Carew JD; Kauh JS; Kim HS
J Vasc Interv Radiol; 2010 Aug; 21(8):1197-204; quiz 204. PubMed ID: 20656222
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma downstaging in liver transplantation.
Yu CY; Ou HY; Huang TL; Chen TY; Tsang LL; Chen CL; Cheng YF
Transplant Proc; 2012 Mar; 44(2):412-4. PubMed ID: 22410030
[TBL] [Abstract][Full Text] [Related]
4. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
[TBL] [Abstract][Full Text] [Related]
5. Living donor liver transplantation for hepatocellular carcinoma.
Isik B; Ince V; Karabulut K; Kayaalp C; Yilmaz S
Transplant Proc; 2012; 44(6):1713-6. PubMed ID: 22841251
[TBL] [Abstract][Full Text] [Related]
6. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
7. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
8. Tumor biology and pre-transplant locoregional treatments determine outcomes in patients with T3 hepatocellular carcinoma undergoing liver transplantation.
Kim PT; Onaca N; Chinnakotla S; Davis GL; Jennings LW; McKenna GJ; Ruiz RM; Levy MF; Goldstein R; Klintmalm GB
Clin Transplant; 2013; 27(2):311-8. PubMed ID: 23351129
[TBL] [Abstract][Full Text] [Related]
9. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?
Chan AC; Chan SC; Chok KS; Cheung TT; Chiu DW; Poon RT; Fan ST; Lo CM
Liver Transpl; 2013 Apr; 19(4):411-9. PubMed ID: 23447460
[TBL] [Abstract][Full Text] [Related]
10. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival.
Bharat A; Brown DB; Crippin JS; Gould JE; Lowell JA; Shenoy S; Desai NM; Chapman WC
J Am Coll Surg; 2006 Oct; 203(4):411-20. PubMed ID: 17000383
[TBL] [Abstract][Full Text] [Related]
11. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
12. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
Jin YJ; Shim JH; Lee HC; Yoo DJ; Kim KM; Lim YS; Suh DJ
J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
[TBL] [Abstract][Full Text] [Related]
13. Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma.
An HJ; Jang JW; Bae SH; Choi JY; Yoon SK; Lee MA; You YK; Kim DG; Jung ES
Liver Transpl; 2012 Dec; 18(12):1406-14. PubMed ID: 22821639
[TBL] [Abstract][Full Text] [Related]
14. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma.
Choi HJ; Kim DG; Na GH; Hong TH; You YK
Transplant Proc; 2012 Mar; 44(2):399-402. PubMed ID: 22410027
[TBL] [Abstract][Full Text] [Related]
15. Outcomes after curative treatment for cryptogenic cirrhosis-associated hepatocellular carcinoma satisfying the Milan criteria.
Takuma Y; Nouso K; Makino Y; Gotoh T; Toshikuni N; Morimoto Y; Shimomura H; Yamamoto H
J Gastroenterol Hepatol; 2011 Sep; 26(9):1417-24. PubMed ID: 21884248
[TBL] [Abstract][Full Text] [Related]
16. Living donor liver transplantation for hepatocellular carcinoma: the impact of neo-adjuvant treatments on the long term results.
Di Sandro S; Giacomoni A; Slim A; Lauterio A; Mangoni I; Mihaylov P; Pirotta V; Aseni P; De Carlis L
Hepatogastroenterology; 2012; 59(114):505-10. PubMed ID: 22353516
[TBL] [Abstract][Full Text] [Related]
17. Primary versus salvage living donor liver transplantation for patients with hepatocellular carcinoma: impact of microvascular invasion on survival.
Moon JI; Kwon CH; Joh JW; Choi GS; Jung GO; Kim JM; Shin M; Choi SJ; Kim SJ; Lee SK
Transplant Proc; 2012 Mar; 44(2):487-93. PubMed ID: 22410053
[TBL] [Abstract][Full Text] [Related]
18. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
Na GH; Kim EY; Hong TH; You YK; Kim DG
HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
[TBL] [Abstract][Full Text] [Related]
19. Necrosis percentage of radiologically treated hepatocellular carcinoma at hepatectomy for liver transplantation.
Rossetto A; Adani GL; Baccarani U; Bresadola V; Lorenzin D; Sponza M; Vit A; De Anna D; Bresadola F
Transplant Proc; 2011 May; 43(4):1095-7. PubMed ID: 21620061
[TBL] [Abstract][Full Text] [Related]
20. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
